StockData

Mannatech vs Natural Alternatives International

MTEX and NAII side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MTEX and NAII compare

Natural Alternatives International is the larger company, worth 3.6 times as much as Mannatech ($19.9M against $5.5M).

Natural Alternatives International grew revenue faster over the last twelve months (9.7% versus −5.0% for Mannatech).

Mannatech keeps more of each dollar of sales as profit, with a net margin of −6.9% compared with −14.5% at Natural Alternatives International.

Mannatech scores higher on the StockData Score (8 against 6 for Natural Alternatives International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMTEXNAII
Size and price
Market cap$5.5M$19.9M
Share price$2.83$0.901
Change, 1 year−70.5%−71.6%
Change, 5 years−92.6%−93.1%
Beta (5Y)0.800.11
Employees387219
StockData Score
Total score8 (better)6
Valuation score2 (better)1
Growth score11
Performance score12 (better)
Health score4 (better)2
Dividend score00
Valuation
P/S0.1× (better)0.1×
P/B–0.4×
EV/EBITDA0.6×–
P/FCF3.4×–
FCF yield29.2% (better)−63.3%
Growth
Revenue growth (TTM)−5.0%9.7% (better)
Revenue growth, 5Y average−6.5%−4.4% (better)
Profitability
Gross margin76.1% (better)6.3%
Operating margin2.5% (better)−13.2%
Net margin−6.9% (better)−14.5%
FCF margin1.5% (better)−8.9%
Return on equity−406%−35.0% (better)
Return on invested capital–−25.2%
Financial health
Debt / equity–0.20
Net debt / EBITDA−0.89–
Interest coverage5.9×–
Current ratio1.151.73 (better)
Altman Z-score3.83 (better)1.49
Piotroski F-score22
Dividends and buybacks
Buyback yield–0.45%
Shareholder yield0.00%0.45% (better)
Ownership
Held by institutions7.9%10.5%
Held by insiders–5.0%
Insider net buying, 12 months$62.2K (better)$26.8K
Short interest, % of float–0.03%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.